Molecular structure of N-Desalkyl itraconazole, CAS Number: 89848-41-9
N-Desalkyl itraconazole (CAS 89848-41-9)
Alternate Names:
cis-4-[4-[4-[4-[[2-(2,4-Dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-1-piperazinyl]phenyl]-2,4-dihydro-3H-1,2,4-triazol-3-one
CAS Number:
89848-41-9
Molecular Weight:
649.53
Molecular Formula:
C31H30Cl2N8O4
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
N-Desalkyl-itraconazole is believed to exert its effects through the inhibition of ergosterol synthesis, an essential component of fungal cell membranes. Ergosterol plays a vital role in maintaining the integrity and proper functioning of fungal cell membranes. By impeding its synthesis, N-Desalkyl-itraconazole disrupts the structure and function of the cell membrane, ultimately leading to the demise of the fungus. Notably, it has exhibited notable efficacy as an inhibitor of Candida albicans, a prevalent causative agent of fungal infections. Moreover, its potential applications extend to the treatment of other fungal infections caused by species such as Aspergillus and Cryptococcus. This application highlights its potential to combat fungal contamination and ensure the safety and longevity of food products. Additionally, its insecticidal properties have been explored, suggesting potential applications as an insecticide.
N-Desalkyl itraconazole (CAS 89848-41-9) References
- Role of itraconazole metabolites in CYP3A4 inhibition. | Isoherranen, N., et al. 2004. Drug Metab Dispos. 32: 1121-31. PMID: 15242978
- Hydroxyitraconazole, formed during intestinal first-pass metabolism of itraconazole, controls the time course of hepatic CYP3A inhibition and the bioavailability of itraconazole in rats. | Quinney, SK., et al. 2008. Drug Metab Dispos. 36: 1097-101. PMID: 18339815
- The enzymatic basis of drug-drug interactions with systemic triazole antifungals. | Nivoix, Y., et al. 2008. Clin Pharmacokinet. 47: 779-92. PMID: 19026034
- Drug interaction between itraconazole and bortezomib: exacerbation of peripheral neuropathy and thrombocytopenia induced by bortezomib. | Iwamoto, T., et al. 2010. Pharmacotherapy. 30: 661-5. PMID: 20575631
- A simple, sensitive HPLC-PDA method for the quantification of itraconazole and hydroxy itraconazole in human serum: a reference laboratory experience. | Cendejas-Bueno, E., et al. 2013. Diagn Microbiol Infect Dis. 76: 314-20. PMID: 23588004
- Itraconazole and clarithromycin as ketoconazole alternatives for clinical CYP3A inhibition studies. | Ke, AB., et al. 2014. Clin Pharmacol Ther. 95: 473-6. PMID: 24747234
- Dealing with the complex drug-drug interactions: towards mechanistic models. | Varma, MV., et al. 2015. Biopharm Drug Dispos. 36: 71-92. PMID: 25545151
- Plasma Protein Binding of Challenging Compounds. | Riccardi, K., et al. 2015. J Pharm Sci. 104: 2627-36. PMID: 26037784
- Evaluation of Ketoconazole and Its Alternative Clinical CYP3A4/5 Inhibitors as Inhibitors of Drug Transporters: The In Vitro Effects of Ketoconazole, Ritonavir, Clarithromycin, and Itraconazole on 13 Clinically-Relevant Drug Transporters. | Vermeer, LM., et al. 2016. Drug Metab Dispos. 44: 453-9. PMID: 26668209
- Simultaneous determination of itraconazole, hydroxy itraconazole, keto itraconazole and N-desalkyl itraconazole concentration in human plasma using liquid chromatography with tandem mass spectrometry. | Liang, X., et al. 2016. J Chromatogr B Analyt Technol Biomed Life Sci. 1020: 111-9. PMID: 27038403
- Corrigendum to 'Simultaneous determination of itraconazole, hydroxy itraconazole, keto itraconazole and N-desalkyl itraconazole concentration in human plasma using liquid chromatography with tandem mass spectrometry' [J. Chromatogr. B 1020 (2016) 111-119]. | Liang, X., et al. 2016. J Chromatogr B Analyt Technol Biomed Life Sci. 1029-1030: 239. PMID: 27475407
- Physiologically Based Pharmacokinetic Model of Itraconazole and Two of Its Metabolites to Improve the Predictions and the Mechanistic Understanding of CYP3A4 Drug-Drug Interactions. | Prieto Garcia, L., et al. 2018. Drug Metab Dispos. 46: 1420-1433. PMID: 30068519
- Simultaneous determination of itraconazole and its CYP3A4-mediated metabolites including N-desalkyl itraconazole in human plasma using liquid chromatography-tandem mass spectrometry and its clinical application. | Imoto, Y., et al. 2020. J Pharm Health Care Sci. 6: 11. PMID: 32391164
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
N-Desalkyl itraconazole, 10 mg | sc-500110 | 10 mg | $406.00 | |||
N-Desalkyl itraconazole, 50 mg | sc-500110A | 50 mg | $3252.00 | |||
N-Desalkyl itraconazole, 250 mg | sc-500110B | 250 mg | $12839.00 |